XTL Biopharmaceuticals director reports 1M options

Q: What does Osnat Hillel Fain report on the XTLB Form 3 filing?

The Form 3 reports that director Osnat Hillel Fain holds options linked to 1,000,000 underlying Ordinary Shares of XTL Biopharmaceuticals Ltd. These options represent an existing derivative position rather than a new share purchase or sale.

Q: What are the key terms of the options reported for XTLB?

The reported options relate to 1,000,000 underlying Ordinary Shares with an exercise price of $0.014 per share. They carry an expiration date of March 17, 2029, defining how long the director can choose to exercise them under these terms.

Q: How do the XTLB director’s options vest over time?

The option vests in three equal annual installments, beginning on March 17, 2024. This means one-third of the total option amount becomes exercisable each year over a three-year period, aligning vesting with continued service or time-based conditions.

Q: Is the XTLB Form 3 filing a buy or sell transaction?

The Form 3 reflects holdings of options rather than a new buy or sell transaction. It provides an initial statement of beneficial ownership, showing the director’s option position and its terms, including exercise price, vesting schedule, and expiration date.

XTL Biopharmaceuticals Ltd director Osnat Hillel Fain has reported an existing options holding on a Form 3.

Accepted by SEC EDGAR 03/23/2026 - 04:01 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd director Osnat Hillel Fain has reported an existing options holding on a Form 3. The filing shows options over 1,000,000 underlying Ordinary Shares with an exercise price of $0.014 per share and an expiration date of March 17, 2029.

According to the disclosure, the option vests in three equal annual installments beginning on March 17, 2024. The exercise price was originally set in New Israeli Shekels and is presented in U.S. dollars based on a Bank of Israel exchange rate of NIS 3.1190 = USD 1.00 reported on March 19, 2026.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Hillel Fain Osnat

Role Director

Type	Security	Shares	Price	Value
Holding	Options	--	--	--

Holdings: Options — 1,000,000 contracts (Direct)

Footnotes (2)

F1. The option vests in three equal annual installments beginning on March 17, 2024.
F2. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 0.0438, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 19, 2026, which was NIS 3.1190 = USD 1.00.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Osnat Hillel Fain report on the XTLB Form 3 filing?

The Form 3 reports that director Osnat Hillel Fain holds options linked to 1,000,000 underlying Ordinary Shares of XTL Biopharmaceuticals Ltd. These options represent an existing derivative position rather than a new share purchase or sale.

What are the key terms of the options reported for XTLB?

The reported options relate to 1,000,000 underlying Ordinary Shares with an exercise price of $0.014 per share. They carry an expiration date of March 17, 2029, defining how long the director can choose to exercise them under these terms.

How do the XTLB director’s options vest over time?

The option vests in three equal annual installments, beginning on March 17, 2024. This means one-third of the total option amount becomes exercisable each year over a three-year period, aligning vesting with continued service or time-based conditions.

How was the XTLB options exercise price converted to U.S. dollars?

The option exercise price was initially denominated in New Israeli Shekels at NIS 0.0438. It is presented in U.S. dollars using a Bank of Israel exchange rate of NIS 3.1190 = USD 1.00, reported on March 19, 2026, resulting in the $0.014 figure.

Is the XTLB Form 3 filing a buy or sell transaction?

The Form 3 reflects holdings of options rather than a new buy or sell transaction. It provides an initial statement of beneficial ownership, showing the director’s option position and its terms, including exercise price, vesting schedule, and expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hillel Fain Osnat

(Last)

(First)

(Middle)

26 BEN-GURION ST.

(Street)

RAMAT GAN

5112001

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
XTL BIOPHARMACEUTICALS LTD [ XTLB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options	⁽¹⁾	03/17/2029	Ordinary Shares	1,000,000	$0.014⁽²⁾	D

Explanation of Responses:

1. The option vests in three equal annual installments beginning on March 17, 2024.

2. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 0.0438, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 19, 2026, which was NIS 3.1190 = USD 1.00.

	/s/ Osnat Hillel Fain	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR